The vaccine maker said deliveries for some contracts are now expected next year
PHOTO
Moderna Inc on Thursday cut the annual sales forecast for its COVID-19 vaccine to between $18 billion and $19 billion from $21 billion, citing short-term supply constraints.
It did not disclose further details on the supply issues. The vaccine maker said deliveries for some contracts are now expected next year.
It reported sales of $3.40 billion in the third quarter, missing Wall Street estimates of $3.53 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
Reuters
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
© ZAWYA 2024
